Eli Lilly and Company (NYSE:LLY) – Research analysts at Leerink Swann raised their Q2 2017 earnings per share (EPS) estimates for shares of Eli Lilly and Company in a research report issued on Monday. Leerink Swann analyst S. Fernandez now forecasts that the company will post earnings of $1.04 per share for the quarter, up from their previous forecast of $1.03. Leerink Swann currently has a “Outperform” rating on the stock. Leerink Swann also issued estimates for Eli Lilly and Company’s Q3 2017 earnings at $1.00 EPS, FY2017 earnings at $4.09 EPS, FY2019 earnings at $4.85 EPS, FY2020 earnings at $5.23 EPS and FY2021 earnings at $5.58 EPS.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.96 by $0.02. The firm had revenue of $5.23 billion for the quarter, compared to analysts’ expectations of $5.22 billion. Eli Lilly and Company had a return on equity of 26.64% and a net margin of 10.13%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.83 EPS.

COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/08/q2-2017-earnings-estimate-for-eli-lilly-and-company-issued-by-leerink-swann-nyselly-updated-updated-updated.html.

Several other brokerages have also issued reports on LLY. Piper Jaffray Companies reiterated a “buy” rating and issued a $100.00 price target on shares of Eli Lilly and Company in a report on Monday, April 17th. Credit Suisse Group reiterated a “buy” rating on shares of Eli Lilly and Company in a report on Tuesday, March 21st. Argus lowered Eli Lilly and Company from a “buy” rating to a “hold” rating and raised their target price for the company from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Jefferies Group LLC restated a “buy” rating and issued a $93.00 target price on shares of Eli Lilly and Company in a report on Thursday, June 22nd. Finally, Sanford C. Bernstein restated an “outperform” rating and issued a $88.00 target price on shares of Eli Lilly and Company in a report on Sunday, May 21st. Two analysts have rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company. Eli Lilly and Company presently has an average rating of “Hold” and an average target price of $87.78.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 84.02 on Wednesday. The company has a market cap of $88.75 billion, a PE ratio of 40.63 and a beta of 0.35. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The firm has a 50-day moving average price of $80.49 and a 200 day moving average price of $79.95.

A number of institutional investors have recently bought and sold shares of LLY. First Command Financial Services Inc. boosted its position in Eli Lilly and Company by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares during the last quarter. Heritage Trust Co acquired a new position in Eli Lilly and Company during the first quarter valued at approximately $135,000. Point72 Asia Hong Kong Ltd boosted its position in Eli Lilly and Company by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares during the last quarter. LeJeune Puetz Investment Counsel LLC acquired a new position in Eli Lilly and Company during the fourth quarter valued at approximately $136,000. Finally, Penserra Capital Management LLC boosted its position in Eli Lilly and Company by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares during the last quarter. Institutional investors and hedge funds own 75.41% of the company’s stock.

In related news, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the completion of the transaction, the vice president now directly owns 62,056 shares in the company, valued at $4,962,618.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the transaction, the insider now owns 124,265,804 shares of the company’s stock, valued at $10,491,761,831.72. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 474,733 shares of company stock valued at $39,634,487. 0.20% of the stock is owned by company insiders.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.48%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and Company’s payout ratio is 100.48%.

Eli Lilly and Company Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and Company (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.